Denali Therapeutics Inc.
DNLI
$15.15
$0.261.75%
12/31/2024 | 09/30/2024 | ||||
---|---|---|---|---|---|
Revenue | -- | -- | |||
Total Other Revenue | -- | -- | |||
Total Revenue | -- | -- | |||
Cost of Revenue | 1.58% | 583.92% | |||
Gross Profit | -1.58% | -583.92% | |||
SG&A Expenses | 20.48% | -0.97% | |||
Depreciation & Amortization | -- | -- | |||
Other Operating Expenses | -- | -- | |||
Total Operating Expenses | 5.41% | 5.66% | |||
Operating Income | -5.41% | -5.66% | |||
Income Before Tax | -6.99% | -8.25% | |||
Income Tax Expenses | -- | -- | |||
Earnings from Continuing Operations | -7.05% | -8.25% | |||
Earnings from Discontinued Operations | -- | -- | |||
Extraordinary Item & Accounting Change | -- | -- | |||
Minority Interest in Earnings | -- | -- | |||
Net Income | -7.05% | -8.25% | |||
EBIT | -5.41% | -5.66% | |||
EBITDA | -7.16% | -5.47% | |||
EPS Basic | -6.66% | -7.86% | |||
Normalized Basic EPS | -12.32% | -7.86% | |||
EPS Diluted | -6.66% | -7.22% | |||
Normalized Diluted EPS | -12.32% | -7.86% | |||
Average Basic Shares Outstanding | 0.37% | 0.37% | |||
Average Diluted Shares Outstanding | 0.37% | 0.37% | |||
Dividend Per Share | -- | -- | |||
Payout Ratio | -- | -- |